Affiliation:
1. Chemical Injuries Research Center, Systems Biology and Poisonings Institute , Baqiyatallah University of Medical Sciences , Tehran , Iran
Abstract
Abstract
Sulphur mustard (SM) is a powerful blister-causing alkylating chemical warfare agent used by Iraqi forces against Iran. One of the known complications of mustard gas inhalation is mustard lung which is discussed as a phenotype of chronic obstructive pulmonary disease (COPD). In this complication, there are clinical symptoms close to COPD with common etiologies, such as in smokers. Based on information gradually obtained by conducting the studies on mustard lung patients, systemic symptoms along with pulmonary disorders have attracted the attention of researchers. Changes in serum levels of inflammatory markers, such as C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), nuclear factor κB (NF-κB), matrix metalloproteinases (MMPs), interleukin (IL), chemokines, selectins, immunoglobulins, and signs of imbalance in oxidant-antioxidant system at serum level, present the systemic changes in these patients. In addition to these, reports of extra-pulmonary complications, such as osteoporosis and cardiovascular disease are also presented. In this study, the chance of developing the systemic nature of this lung disease have been followed on using the comparative study of changes in the mentioned markers in mustard lung and COPD patients at stable phases and the mechanisms of pathogenesis and phenomena, such as airway remodeling in these patients.
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology
Reference145 articles.
1. Adamson IY, Bowden DH. (1974). The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol77: 185–197.
2. Agin K. (2004). Comparison of prevalence of osteoporosis in patients with asthma following chemical injury in patients with asthma Sulfur-mustard non chemical victims. Mil Res J4: 419–422.
3. Agusti A, Soriano JB. (2008). COPD as a systemic disease. COPD: Journal of Chronic Obstructive Pulmonary Disease5: 133–138.10.1080/15412550801941349
4. Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janciauskiene S. (2004). Analysis of systemic biomarkers in COPD patients. Copd1: 155–164.
5. Anderson GP. (2006). COPD, asthma and C-reactive protein. Eur Respir J27: 874–876.10.1183/09031936.06.00029306
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献